Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) was up 2.5% during trading on Monday . The stock traded as high as $4.20 and last traded at $4.12, with a volume of 282,799 shares traded. The stock had previously closed at $4.02.

Several equities research analysts recently commented on TTPH shares. Wedbush reiterated a “neutral” rating and issued a $4.00 price objective on shares of Tetraphase Pharmaceuticals in a report on Monday, June 20th. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research note on Wednesday, July 6th. Gabelli downgraded Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating and set a $7.00 price target for the company. in a research note on Friday, May 13th. BMO Capital Markets started coverage on Tetraphase Pharmaceuticals in a research note on Monday, April 11th. They set a “market perform” rating and a $8.00 price target for the company. Finally, Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Saturday, May 14th. Twelve research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Tetraphase Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $20.80.

The firm’s market cap is $153.38 million. The company has a 50-day moving average price of $4.14 and a 200-day moving average price of $4.54.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by $0.02. During the same period in the previous year, the business posted ($0.66) EPS. The business earned $2 million during the quarter, compared to the consensus estimate of $2.20 million. The business’s revenue was down 33.3% compared to the same quarter last year. Equities analysts anticipate that Tetraphase Pharmaceuticals Inc. will post ($1.96) earnings per share for the current year.

An institutional investor recently raised its position in Tetraphase Pharmaceuticals stock. California Public Employees Retirement System raised its position in shares of Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) by 1,459.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 276,000 shares of the biopharmaceutical company’s stock after buying an additional 258,300 shares during the period. California Public Employees Retirement System owned 0.76% of Tetraphase Pharmaceuticals worth $2,768,000 as of its most recent SEC filing.

Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.